BR112017008525A2 - proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. - Google Patents
proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo.Info
- Publication number
- BR112017008525A2 BR112017008525A2 BR112017008525-9A BR112017008525A BR112017008525A2 BR 112017008525 A2 BR112017008525 A2 BR 112017008525A2 BR 112017008525 A BR112017008525 A BR 112017008525A BR 112017008525 A2 BR112017008525 A2 BR 112017008525A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- alleviating
- symptom
- disorder
- treating
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 208000027866 inflammatory disease Diseases 0.000 title 2
- 208000024891 symptom Diseases 0.000 title 2
- 206010061218 Inflammation Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 11
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 11
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 241000270295 Serpentes Species 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Abstract
esta invenção se refere a moléculas, particularmente polipeptídeos, mais particularmente proteínas de fusão que incluem um polipeptídeo de serpina ou uma sequência de aminoácidos que é derivada de uma serpina e um segundo polipeptídeo compreendendo pelo menos um do seguinte: um polipeptídeo fc ou uma sequência de aminoácidos que é derivada de um polipeptídeo fc; um polipeptídeo alvejado por citocina ou uma sequência derivada a partir de um polipeptídeo alvejado por citocina; um polipeptídeo contendo um domínio wap ou uma sequência derivada a partir de um polipeptídeo contendo um domínio wap; e um polipeptídeo de albumina ou um sequência de aminoácidos que é derivada de um polipeptídeo de albumina sérica. esta invenção também se refere a métodos de uso tais moléculas em uma variedade de indicações terapêuticas e diagnósticas, bem como métodos de produção de tais moléculas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/524832 | 2014-10-27 | ||
US14/524,832 US10400029B2 (en) | 2011-06-28 | 2014-10-27 | Serpin fusion polypeptides and methods of use thereof |
PCT/US2015/057533 WO2016069574A1 (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017008525A2 true BR112017008525A2 (pt) | 2018-01-30 |
Family
ID=55858243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017008525-9A BR112017008525A2 (pt) | 2014-10-27 | 2015-10-27 | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP3212290A4 (pt) |
JP (2) | JP6737781B2 (pt) |
KR (2) | KR20240005109A (pt) |
CN (2) | CN107206257A (pt) |
AU (2) | AU2015339507B2 (pt) |
BR (1) | BR112017008525A2 (pt) |
CA (1) | CA2965151A1 (pt) |
HK (1) | HK1244460A1 (pt) |
IL (2) | IL251799B2 (pt) |
MX (2) | MX2017005467A (pt) |
RU (1) | RU2746550C2 (pt) |
SG (2) | SG11201703390SA (pt) |
UA (1) | UA127305C2 (pt) |
WO (1) | WO2016069574A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3117961A1 (en) * | 2018-10-29 | 2020-05-07 | Spin Therapeutics, Llc | Compositions and methods for alpha-1-antitrypsin disorders |
CN111989340A (zh) * | 2018-11-18 | 2020-11-24 | 杭州博虎生物科技有限公司 | 一种重组人白细胞介素10融合蛋白及其应用 |
CN112315897A (zh) * | 2020-11-04 | 2021-02-05 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法 |
US20240067703A1 (en) * | 2020-12-21 | 2024-02-29 | Macquarie University | Treatment of glaucoma |
GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
WO2022184854A2 (en) * | 2021-03-03 | 2022-09-09 | Formycon Ag | Formulations of ace2 fc fusion proteins |
CN113325181A (zh) * | 2021-04-25 | 2021-08-31 | 苏州市立医院(北区) | 丝氨酸蛋白酶抑制剂在用于脓毒症早期预警的标志物中的应用 |
CN114874333A (zh) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
US20230364208A1 (en) | 2022-05-16 | 2023-11-16 | Inhibrx, Inc. | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1161532A1 (en) * | 1999-03-01 | 2001-12-12 | Human Genome Sciences, Inc. | Human serpin proteins |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
UY28423A1 (es) * | 2003-07-18 | 2005-02-28 | Vertex Pharma | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- |
WO2005019434A2 (en) * | 2003-08-26 | 2005-03-03 | The Regents Of The University Of Colorado, A Body Corporate | Serine protease inhibitors for treatment of bacterial infections |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CN102746404B (zh) * | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
NZ565511A (en) * | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
MX2008002101A (es) * | 2005-08-12 | 2008-04-19 | Schering Corp | Fusiones de la proteina-1 quimiotactica de monocito. |
EP2671891A3 (en) * | 2008-06-27 | 2014-03-05 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
SI2786762T1 (sl) * | 2008-12-19 | 2019-07-31 | Macrogenics, Inc. | Kovalentna diatelesa in njihove uporabe |
WO2012087746A1 (en) * | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
PT2691417T (pt) * | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Variantes de fc de anticorpos |
KR20140068861A (ko) * | 2011-06-28 | 2014-06-09 | 인히브릭스 엘엘씨 | Wap 도메인 융합 폴리펩티드 및 이의 이용 방법 |
PL2726092T3 (pl) * | 2011-06-28 | 2019-11-29 | Inhibrx Lp | Polipeptydy fuzyjne serpiny i sposoby ich stosowania |
CA2896951A1 (en) * | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
WO2013192131A1 (en) * | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
RU2015100656A (ru) * | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения |
BR112015002263A2 (pt) * | 2012-08-02 | 2017-12-12 | Hoffmann La Roche | polipeptídeo de fusão, polipeptídeo de fusão dimérico, método para a produção de um receptor fc solúvel, uso de um polipeptídeo de fusão imobilizado e composição farmacêutica |
WO2014089375A1 (en) * | 2012-12-05 | 2014-06-12 | Boston Strategics Corporation | Protein expression enhancing polypeptides |
-
2015
- 2015-10-27 RU RU2017118325A patent/RU2746550C2/ru active
- 2015-10-27 BR BR112017008525-9A patent/BR112017008525A2/pt active Search and Examination
- 2015-10-27 UA UAA201705128A patent/UA127305C2/uk unknown
- 2015-10-27 EP EP15854670.5A patent/EP3212290A4/en active Pending
- 2015-10-27 WO PCT/US2015/057533 patent/WO2016069574A1/en active Application Filing
- 2015-10-27 KR KR1020237043666A patent/KR20240005109A/ko active Application Filing
- 2015-10-27 CN CN201580071331.7A patent/CN107206257A/zh active Pending
- 2015-10-27 MX MX2017005467A patent/MX2017005467A/es unknown
- 2015-10-27 CN CN202111439584.9A patent/CN114316068A/zh active Pending
- 2015-10-27 KR KR1020177014414A patent/KR20170091096A/ko not_active IP Right Cessation
- 2015-10-27 IL IL251799A patent/IL251799B2/en unknown
- 2015-10-27 IL IL308589A patent/IL308589A/en unknown
- 2015-10-27 JP JP2017522654A patent/JP6737781B2/ja active Active
- 2015-10-27 SG SG11201703390SA patent/SG11201703390SA/en unknown
- 2015-10-27 CA CA2965151A patent/CA2965151A1/en active Pending
- 2015-10-27 SG SG10201903142RA patent/SG10201903142RA/en unknown
- 2015-10-27 AU AU2015339507A patent/AU2015339507B2/en active Active
-
2017
- 2017-04-26 MX MX2021012047A patent/MX2021012047A/es unknown
-
2018
- 2018-03-05 HK HK18103148.5A patent/HK1244460A1/zh unknown
-
2020
- 2020-07-16 JP JP2020121953A patent/JP2020180157A/ja active Pending
-
2021
- 2021-09-28 AU AU2021240153A patent/AU2021240153A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL251799B2 (en) | 2024-04-01 |
JP2020180157A (ja) | 2020-11-05 |
MX2017005467A (es) | 2017-11-30 |
JP2017537888A (ja) | 2017-12-21 |
EP3212290A1 (en) | 2017-09-06 |
AU2015339507B2 (en) | 2021-07-01 |
SG11201703390SA (en) | 2017-05-30 |
RU2017118325A (ru) | 2018-11-29 |
IL251799A0 (en) | 2017-06-29 |
MX2021012047A (es) | 2021-11-03 |
SG10201903142RA (en) | 2019-05-30 |
CA2965151A1 (en) | 2016-05-06 |
EP3212290A4 (en) | 2019-01-23 |
RU2746550C2 (ru) | 2021-04-15 |
KR20240005109A (ko) | 2024-01-11 |
AU2021240153A1 (en) | 2021-10-28 |
AU2015339507A1 (en) | 2017-05-11 |
IL251799B1 (en) | 2023-12-01 |
KR20170091096A (ko) | 2017-08-08 |
IL308589A (en) | 2024-01-01 |
HK1244460A1 (zh) | 2018-08-10 |
RU2017118325A3 (pt) | 2019-03-21 |
CN114316068A (zh) | 2022-04-12 |
WO2016069574A1 (en) | 2016-05-06 |
JP6737781B2 (ja) | 2020-08-12 |
UA127305C2 (uk) | 2023-07-19 |
CN107206257A (zh) | 2017-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
CL2018003136A1 (es) | Proteínas de unión específica y usos de las mismas. | |
BR112019001108A2 (pt) | usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc | |
BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
CL2016001968A1 (es) | Proteinas de fusion de interleucina-2 y usos de las mismas | |
BR112018007422A2 (pt) | anticorpos anti-age e métodos de uso dos mesmos | |
PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
GT201200271A (es) | Proteínas que se unen al tnf-a | |
BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
BR112015019879A2 (pt) | Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas | |
BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
BR112017023646A2 (pt) | proteínas agonistas de receptor de cd40 de cadeia simples | |
CU20140034A7 (es) | Proteínas de fusión para tratar trastornos metabólicos | |
BR112016013138A2 (pt) | mistura de peptídeos | |
CO6640254A2 (es) | Método para preparar anticuerpos con propiedades mejoradas | |
IN2013MN02441A (pt) | ||
ECSP13012913A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
GT201200252A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
EA201491481A1 (ru) | Аллергены тимофеевки луговой и способы и применения для модулирования иммунного ответа | |
BR112019004459A2 (pt) | métodos para purificar anticorpos | |
EA201491277A1 (ru) | Противораковый слитый белок | |
BR112016003336A2 (pt) | polipeptídeo; polipeptídeo de fusão; polinucleotídeo; população das variantes de polipeptídeo com base em um scaffold comum; população de polinucleotídeos; combinação de uma população de polipeptídeo; e métodos para selecionar um polipeptídeo desejado tendo uma afinidade com um alvo predeterminado a partir de uma população de polipeptídeos; isolar um polinucleotídeo codificando um polipeptídeo desejado tendo uma afinidade com um alvo predeterminado; identificar um polipeptídeo desejado tendo uma afinidade com um alvo predeterminado; e selecionar e identificar um polipeptídeo desejado tendo uma afinidade com um alvo predeterminado a partir de uma população de polipeptídeos | |
BR112014031841A2 (pt) | formulação farmacêutica | |
BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25A | Requested transfer of rights approved |
Owner name: INHIBRX, INC. (US) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |